Journal of Breast Disease 2016;4(1):1-9
doi:10.14449/jbd.2016.4.1.1
Clinical Implications of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome in the Era of Genomic Medicine: Clinician's Perspectives.
Hyung Seok PARK 1 ; Ji Soo PARK ; Eun Ji NAM ; Seung Tae LEE ; Jung Woo HAN ; Tae Il KIM
Affiliations
Keywords
BRCA1; BRCA2; Breast neoplasms; Genes; High-throughput nucleotide sequencing
Country
Republic of Korea
Language
Korean
MeSH
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
Abstract
Hereditary breast and ovarian cancer syndrome accounts for approximately 5% to 10% of breast or ovarian cancers, with which the high-penetrant BRCA1/2 genes have been associated. With the recent development of next-generation sequencing (NGS), germline mutation testing and its related medical and surgical management have been rapidly changing. In this review, we summarize the current status and perspectives of NGS testing for not only BRCA1/2 but also the other breast and ovarian cancer susceptibility genes.
备案号: 11010502037788, 京ICP备10218182号-8)